Jan 09, 2023 / 06:30PM GMT
Casey Rene Woodring - JPMorgan Chase & Co, Research Division - Research Analyst
All right. Great. Thank you, everybody, for joining us today. I'm Casey Woodring from the Life Science Tools and Diagnostics team here at JPMorgan. Welcome to our conference. Here with me today, we have QIAGEN's, CEO, Thierry Bernard, following Thierry's presentation, we'll have a short Q&A session. But for now, I'll just turn it over to Thierry. Thierry?
Thierry Bernard - Qiagen N.V. - CEO, MD & Member of Management Board
Thank you so much, Casey, and good morning to everybody. I suggest that we are going to wait just a couple of seconds to have everybody getting in. Okay. I think we at -- I think we can start now. So welcome again. Thanks for your interest in QIAGEN. And obviously, in January, a very happy New Year to you all, to your companies. It's a pleasure to be with you again after -- last time I presented here at JPM was in January of 2020. So clearly, 2 years after, I think it's a pleasure to be presential and not only virtual.
And I'd like to spend the
Qiagen NV at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot